November 13, 2024 06:29 AM ESTUpdated 09:06 AM
R&D

Sy­ros' shares plum­met as blood can­cer drug fails again

Ayisha Sharma

News Reporter

Sy­ros Phar­ma­ceu­ti­cals’ stock price nose­dived af­ter its last drug can­di­date flunked a tri­al in hema­to­log­i­cal ma­lig­nan­cies for the sec­ond time in re­cent months.

In a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

A service from the Financial Times